What is the MammaPrint assay for breast cancer?

Updated: Dec 27, 2019
  • Author: Pavani Chalasani, MD, MPH; Chief Editor: John V Kiluk, MD, FACS  more...
  • Print
Answer

The MammaPrint assay (Agendia, The Netherlands) is a genetic test that measures the activity of 70 genes to determine the 5- to 10-year relapse risk for women diagnosed with early breast cancer. It was approved for use by the FDA in 2007 and is an alternative platform to Oncotype DX. MammaPrint test results are reported as either a low-risk or a high-risk RS:

  • A low-risk score means that the cancer has a 10% risk of coming back within 10 years without any additional treatments after surgery

  • A high-risk score means that the cancer has a 29% risk of coming back within 10 years without any additional treatments after surgery


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!